Encouraging preclinical results with T-DM1 (ado-trastuzumab emtansine), consisting of the HER2 antibody trastuzumab conjugated with a cytotoxic agent, exemplifies a new potential treatment for HER2-positive bladder cancers. Here, ERBB2 is linked to urinary bladder cancer.